Activity in terms of reduction of tumor volumes was noted to be significantly enhanced in patients with molecular alterations in the drug targets (RET, VEGFR, EGFR, and PI3K/mTOR), supporting further development of the combination (42). This evidence concerns the gene MTOR and neoplasm.